CD8A and neoplasm: Using EGFR vIII-positive xenografts, combination therapy of olaparib and EGFR vIII-targeted CAR T-cells enhanced anti-tumor immunity by reducing MDSC migration and improving CD8+ T-cell infiltration [144].